

Deborah P M Symmons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6523001/publications.pdf>

Version: 2024-02-01

301
papers

41,093
citations

5430

85
h-index

2823

197
g-index

308
all docs

308
docs citations

308
times ranked

36074
citing authors

#	ARTICLE	IF	CITATIONS
1	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. <i>Rheumatology</i> , 2022, 61, 3930-3938.	0.9	13
2	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <i>Programme Grants for Applied Research</i> , 2022, 10, 1-240.	0.4	0
3	Body Fat Percentage, Waist Circumference, and Obesity As Risk Factors for Rheumatoid Arthritis: A Danish Cohort Study. <i>Arthritis Care and Research</i> , 2019, 71, 777-786.	1.5	40
4	Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2019, 58, 80-85.	0.9	33
5	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 59, 559-567.	0.9	1
6	Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. <i>PLoS ONE</i> , 2019, 14, e0215999.	1.1	13
7	Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. <i>PLoS ONE</i> , 2019, 14, e0201196.	1.1	72
8	Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 384-398.	1.6	12
9	Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. <i>RMD Open</i> , 2018, 4, e000596.	1.8	38
10	Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 50.	1.6	28
11	Long-term persistence with rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1089-1096.	0.9	22
12	Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212426.	0.5	23
13	Multimorbidity is associated with increased disability but lower disease activity over time in patients with RA: results from the BSRBR-RA. <i>Rheumatology</i> , 2018, 57, .	0.9	0
14	Long-term risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Rheumatology</i> , 2018, 57, .	0.9	0
15	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). <i>Arthritis Research and Therapy</i> , 2018, 20, 147.	1.6	73
16	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 1533-1540.	0.9	20
17	Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?. <i>Rheumatology</i> , 2017, 56, kew466.	0.9	0
18	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 654-660.	0.5	122

#	ARTICLE	IF	CITATIONS
19	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 497-503.	0.5	88
20	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	1.8	29
21	Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. <i>Arthritis and Rheumatology</i> , 2017, 69, 1566-1575.	2.9	63
22	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 241-250.	1.0	40
23	Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years. <i>Rheumatology</i> , 2017, 56, 1510-1517.	0.9	10
24	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 17-28.	0.5	918
25	Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. <i>RMD Open</i> , 2017, 3, e000473.	1.8	45
26	Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink. <i>RMD Open</i> , 2017, 3, e000506.	1.8	11
27	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 309-332.	1.1	20
28	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. <i>RMD Open</i> , 2017, 3, e000498.	1.8	25
29	Response to: "Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?" by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e4-e4.	0.5	2
30	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 2402-2403.	2.9	0
31	054. Treatment Decisions Following a Diagnosis of Cancer During Tumor Necrosis Factor Inhibitor Treatment in Patients with Rheumatoid Arthritis. <i>Rheumatology</i> , 2017, 56, .	0.9	0
32	153. Assessment of Predictors of and Outcomes Following Orthopaedic Joint Surgery Over 20 Years in Patients with Early Rheumatoid Arthritis Recruited to the Norfolk Arthritis Register. <i>Rheumatology</i> , 2017, 56, .	0.9	1
33	HLA-DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2618-2628.	2.9	23
34	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 285.	1.6	43
35	Response to: "Evaluation of the association between anticarbamylated protein antibodies and longitudinal course of functional ability in rheumatoid arthritis" by Ajeganova et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e15-e15.	0.5	1
36	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000273.	1.8	8

#	ARTICLE	IF	CITATIONS
37	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1789-1796.	0.5	18
38	Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Rheumatology</i> , 2016, 55, 1601-1609.	0.9	28
39	Risk of <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor \pm : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis: Table 1. <i>Rheumatology</i> , 2016, 55, 1336-1337.	0.9	15
40	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. <i>Rheumatology</i> , 2016, 55, 2033-2039.	0.9	67
41	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1337-1345.	2.9	16
42	Association Between Genetic Variation in <i>FOXO3</i> and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2629-2636.	2.9	32
43	Smoking-Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink. <i>Arthritis Care and Research</i> , 2016, 68, 1598-1606.	1.5	33
44	What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2016, 18, 282.	1.6	21
45	Primary care-based screening for cardiovascular risk factors in patients with psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 348-356.	1.4	26
46	Cardiovascular risk and its modification in patients with connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 81-94.	1.4	12
47	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1797-1805.	0.5	16
48	Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 317-320.	0.5	19
49	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1139-1144.	0.5	41
50	Editorial: Do We Need a Disease-Specific Cardiovascular Risk Calculator for Patients With Rheumatoid Arthritis?. <i>Arthritis and Rheumatology</i> , 2015, 67, 1990-1994.	2.9	10
51	Self-reported pain severity is associated with a history of coronary heart disease. <i>European Journal of Pain</i> , 2015, 19, 167-175.	1.4	17
52	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1121-1132.	0.9	6
53	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. <i>Arthritis Care and Research</i> , 2015, 67, 1637-1645.	1.5	16
54	Patient-reported improvements in health are maintained 2 years after completing a short course of cognitive behaviour therapy, exercise or both treatments for chronic widespread pain: long-term results from the MUSICIAN randomised controlled trial. <i>RMD Open</i> , 2015, 1, e000026-e000026.	1.8	25

#	ARTICLE	IF	CITATIONS
55	Epidemiology research in rheumatology—progress and pitfalls. <i>Nature Reviews Rheumatology</i> , 2015, 11, 631-638.	3.5	8
56	Direct Health Costs of Inflammatory Polyarthritis 10 Years after Disease Onset: Results from the Norfolk Arthritis Register. <i>Journal of Rheumatology</i> , 2015, 42, 794-798.	1.0	5
57	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor- β Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	0.9	0
58	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
59	The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication. <i>Current Rheumatology Reports</i> , 2015, 17, 31.	2.1	13
60	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
61	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2189-2197.	0.3	132
62	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1087-1093.	0.5	162
63	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Lancet, The</i> , 2015, 385, S44.	6.3	10
64	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. <i>Rheumatology</i> , 2015, 54, 1780-1791.	0.9	69
65	Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2099-2102.	0.5	8
66	The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2015, 42, 1448-1454.	1.0	75
67	Epidemiologic concepts and classification of rheumatic and musculoskeletal conditions. , 2015, , 1-8.		0
68	P2. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i34-i35.	0.9	4
69	O23. The Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. <i>Rheumatology</i> , 2014, 53, i38-i38.	0.9	0
70	39. Non-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i70-i70.	0.9	0
71	Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. <i>Arthritis Research and Therapy</i> , 2014, 16, 483.	1.6	51
72	Has the Severity of Rheumatoid Arthritis at Presentation Diminished Over Time?. <i>Journal of Rheumatology</i> , 2014, 41, 1590-1599.	1.0	27

#	ARTICLE	IF	CITATIONS
73	Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor- \pm Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models. <i>Pharmacoeconomics</i> , 2014, 32, 109-134.	1.7	14
74	Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1677-1682.	0.5	34
75	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq1 1 0.784314 rgBT /Overlock	0.5	75
76	Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 787-788.	0.5	8
77	Response to: "The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis" by González-Gayet et al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e28-e28.	0.5	0
78	Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2014, 66, 1296-1301.	1.5	113
79	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 684-690.	0.5	31
80	The burden of musculoskeletal conditions. <i>Medicine</i> , 2014, 42, 190-192.	0.2	7
81	Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis. <i>Value in Health</i> , 2014, 17, 109-115.	0.1	13
82	Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 131-144.	1.6	59
83	Biologics registers in rheumatoid arthritis. <i>Medicine</i> , 2014, 42, 262-265.	0.2	0
84	The role of genetic polymorphisms regulating vitamin D levels in rheumatoid arthritis outcome: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1430-1433.	0.5	11
85	How Do We Classify Rheumatoid Arthritis in Established Disease "Can We Apply the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria?. <i>Journal of Rheumatology</i> , 2014, 41, 2347-2351.	1.0	1
86	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 461-476.	0.4	3
87	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 211-216.	0.5	224
88	Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2013, 65, 122-126.	1.5	19
89	Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. <i>Journal of Investigative Dermatology</i> , 2013, 133, 377-385.	0.3	1,827
90	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. <i>Journal of Rheumatology</i> , 2013, 40, 144-156.	1.0	22

#	ARTICLE	IF	CITATIONS
91	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1517-1523.	0.5	5
92	Learned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis. <i>Rheumatology</i> , 2013, 52, 1233-1238.	0.9	27
93	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 229-234.	0.5	146
94	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , 2013, 52, 91-98.	0.9	116
95	2010 ACR/EULAR classification criteria for rheumatoid arthritis predict increased mortality in patients with early arthritis: results from the Norfolk Arthritis Register. <i>Rheumatology</i> , 2013, 52, 1141-1142.	0.9	5
96	Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 157-163.	2.0	16
97	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 143-144.	0.5	30
98	Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2013, 52, 1905-1913.	0.9	30
99	Modest Association of Joint Hypermobility With Disabling and Limiting Musculoskeletal Pain: Results From a Large-scale General Population-based Survey. <i>Arthritis Care and Research</i> , 2013, 65, 1325-1333.	1.5	79
100	Multivariate meta-analysis of mixed outcomes: a Bayesian approach. <i>Statistics in Medicine</i> , 2013, 32, 3926-3943.	0.8	51
101	The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1315-1320.	0.5	116
102	Investigation of C reactive protein gene polymorphisms as predictors of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1429-1430.	0.5	3
103	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 461-462.	0.5	33
104	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , 2013, 52, 1754-1757.	0.9	79
105	OP0232...Long-Term Effects of Cognitive Behaviour Therapy and Exercise for Chronic Widespread Pain. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A131.1-A131.	0.5	0
106	Cardiovascular Risk in Rheumatic Disease. , 2013, , 505-514.		0
107	Cognitive Behavior Therapy, Exercise, or Both for Treating Chronic Widespread Pain. <i>Archives of Internal Medicine</i> , 2012, 172, 48.	4.3	106
108	Musculoskeletal research--opportunities for all?. <i>Rheumatology</i> , 2012, 51, 1527-1528.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. <i>Journal of Rheumatology</i> , 2012, 39, 240-246.	1.0	67
110	Modifiable risk factors for RA: prevention, better than cure?. <i>Rheumatology</i> , 2012, 51, 499-512.	0.9	90
111	Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literature. <i>Rheumatology</i> , 2012, 51, 216-229.	0.9	18
112	Multiple adverse pregnancy outcomes before symptom onset are associated with a worse disease outcome in women with recent-onset inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 528-533.	0.5	11
113	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 869-874.	0.5	107
114	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. <i>Nature Genetics</i> , 2012, 44, 1336-1340.	9.4	558
115	Influence of Inflammatory Polyarthritis on Quantitative Heel Ultrasound Measurements. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 133.	0.8	1
116	Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R109.	1.6	18
117	Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. <i>Arthritis Care and Research</i> , 2012, 64, 1108-1115.	1.5	81
118	Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1225-1232.	1.5	39
119	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , 2011, 50, 124-131.	0.9	564
120	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1810-1814.	0.5	173
121	The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Rheumatology</i> , 2011, 50, 78-84.	0.9	32
122	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. <i>Arthritis Research and Therapy</i> , 2011, 13, R159.	1.6	26
123	What is the outcome of RA in 2011 and can we predict it?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 485-496.	1.4	23
124	Delivery of paediatric rheumatology care in the UK—the projected shortfall. <i>Clinical Rheumatology</i> , 2011, 30, 679-683.	1.0	6
125	Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 119-130.	0.9	259
126	Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2011, 63, 945-952.	1.5	30

#	ARTICLE	IF	CITATIONS
127	Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: Results from the Norfolk arthritis register. <i>Arthritis Care and Research</i> , 2011, 63, 1745-1752.	1.5	22
128	The relationship between oral contraceptive use and functional outcome in women with recent-onset inflammatory polyarthritis: Results from the Norfolk Arthritis Register. <i>Arthritis and Rheumatism</i> , 2011, 63, 2183-2191.	6.7	21
129	Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 583-589.	0.5	188
130	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 823-826.	0.5	154
131	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. <i>Rheumatology</i> , 2011, 50, 117-123.	0.9	77
132	In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1428-1432.	0.5	18
133	Bone Health in Adult Men and Women with a History of Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 1689-1693.	1.0	29
134	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1831-1834.	0.5	62
135	Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 642-645.	0.5	12
136	Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. <i>Nature Reviews Rheumatology</i> , 2011, 7, 399-408.	3.5	320
137	Are Lipid Ratios Less Susceptible to Change With Systemic Inflammation Than Individual Lipid Components in Patients With Rheumatoid Arthritis?. <i>Angiology</i> , 2011, 62, 167-175.	0.8	60
138	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2011, 50, 1341-1342.	0.9	43
139	Disease Activity, Smoking, and Reproductive-related Predictors of Poor Prognosis in Patients with Very Early Inflammatory Polyarthritis. <i>Journal of Rheumatology</i> , 2011, 38, 429-433.	1.0	2
140	UK rheumatology consultant workforce provision 2007-9: results from the BSR/Arthritis Research UK Consultant Workforce Register. <i>Clinical Medicine</i> , 2011, 11, 119-124.	0.8	12
141	Antibodies to citrullinated ð-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1095-1098.	0.5	48
142	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. <i>Rheumatology</i> , 2011, 50, 146-151.	0.9	18
143	The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?. <i>Seminars in Oncology</i> , 2010, 37, 11-19.	0.8	4
144	The burden of musculoskeletal conditions. <i>Medicine</i> , 2010, 38, 126-128.	0.2	6

#	ARTICLE	IF	CITATIONS
145	Influence of arthritis and non-arthritis related factors on areal bone mineral density (BMDa) in women with longstanding inflammatory polyarthritis: a primary care based inception cohort. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 106.	0.8	2
146	Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 21.	1.0	28
147	Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. <i>Arthritis Care and Research</i> , 2010, 62, 345-353.	1.5	30
148	Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register. <i>Arthritis Care and Research</i> , 2010, 62, 755-763.	1.5	168
149	Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. <i>Arthritis Care and Research</i> , 2010, 62, 664-675.	1.5	38
150	Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. <i>Arthritis Care and Research</i> , 2010, 62, 676-682.	1.5	13
151	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
152	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
153	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2010, 62, 3145-3153.	6.7	72
154	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	13.7	737
155	Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1086-1091.	0.5	185
156	Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 503-509.	0.5	104
157	Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss. <i>Rheumatology</i> , 2010, 49, 1943-1948.	0.9	23
158	Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010, 49, 563-570.	0.9	107
159	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register: reply. <i>Rheumatology</i> , 2010, 49, 1794-1794.	0.9	0
160	Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010, 49, 697-705.	0.9	112
161	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 522-528.	0.5	606
162	Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 689-695.	0.5	41

#	ARTICLE	IF	CITATIONS
163	Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1660-1664.	0.5	18
164	The relationship between post-onset pregnancy and functional outcome in women with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1834-1837.	0.5	20
165	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010, 49, 1570-1577.	0.9	73
166	Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 683-688.	0.5	135
167	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.5	152
168	EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 325-331.	0.5	1,157
169	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
170	Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 367-372.	0.5	80
171	Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor \pm therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 209-215.	0.5	200
172	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. <i>American Journal of Epidemiology</i> , 2009, 169, 909-917.	1.6	71
173	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. <i>Rheumatology</i> , 2009, 48, 1323-1327.	0.9	50
174	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or <i>PTPN22</i> susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 69-74.	0.5	240
175	European biologicals registers: methodology, selected results and perspectives. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1240-1246.	0.5	114
176	Association of functional outcome with both personal and area level socioeconomic inequalities in patients with inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1297-1304.	6.7	34
177	The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. <i>Quality of Life Research</i> , 2009, 18, 1195-205.	1.5	51
178	Same question, different answers: a comparison of global health assessments using visual analogue scales. <i>Quality of Life Research</i> , 2009, 18, 1285-1292.	1.5	13
179	Specific interaction between genotype, smoking and autoimmunity to citrullinated β -enolase in the etiology of rheumatoid arthritis. <i>Nature Genetics</i> , 2009, 41, 1319-1324.	9.4	282
180	Why Do Patients with Inflammatory Arthritis Often Score States "Worse than Death" on the EQ-5D? An Investigation of the EQ-5D Classification System. <i>Value in Health</i> , 2009, 12, 1026-1034.	0.1	28

#	ARTICLE	IF	CITATIONS
181	Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. <i>Arthritis Research and Therapy</i> , 2009, 11, R52.	1.6	173
182	Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 57-62.	0.5	77
183	Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes. <i>Arthritis and Rheumatism</i> , 2008, 58, 370-375.	6.7	44
184	Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 359-369.	6.7	161
185	The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 985-989.	6.7	56
186	Reply to letter by Lippi et al commenting on the relationship between serum vitamin D levels and levels of inflammation markers. <i>Arthritis and Rheumatism</i> , 2008, 58, 1882-1882.	6.7	3
187	Health state utility values: A description of their development and application for rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2008, 59, 1018-1026.	6.7	24
188	Ischemic stroke: Another feature of accelerated atherosclerosis in rheumatoid arthritis?. <i>Arthritis and Rheumatism</i> , 2008, 59, 1051-1053.	6.7	0
189	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. <i>Rheumatology</i> , 2008, 47, 1000-1005.	0.9	67
190	An update on UK rheumatology consultant workforce provision: the BSR/ARC Workforce Register 2005-07: assessing the impact of recent changes in NHS provision. <i>Rheumatology</i> , 2008, 47, 1065-1069.	0.9	10
191	The British Society for Rheumatology Biologics Register: 6 years on. <i>Rheumatology</i> , 2008, 47, 1441-1443.	0.9	53
192	Epidemiology and rheumatology: how can epidemiologists affect treatment strategies?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 1-1.	3.2	0
193	The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. <i>Journal of Rheumatology</i> , 2008, 35, 592-602.	1.0	52
194	Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. <i>Journal of Rheumatology</i> , 2008, 35, 883-90.	1.0	87
195	Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 945-9.	1.0	17
196	The role of specialists in managing established rheumatoid arthritis. <i>Rheumatology</i> , 2007, 47, 237-238.	0.9	4
197	Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. <i>Rheumatology</i> , 2007, 46, 1819-1823.	0.9	18
198	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 389-393.	0.5	36

#	ARTICLE	IF	CITATIONS
199	The overall status in rheumatoid arthritis (OSRA) measure—further evidence to support its use in clinical practice. <i>Rheumatology</i> , 2007, 46, 849-855.	0.9	7
200	Classification criteria for rheumatoid arthritis—time to abandon rheumatoid factor?. <i>Rheumatology</i> , 2007, 46, 725-726.	0.9	35
201	Lymphoma and rheumatoid arthritis—again. <i>Rheumatology</i> , 2007, 46, 1-2.	0.9	34
202	What effects might anti-TNF α treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF α in cardiovascular pathophysiology. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1132-1136.	0.5	107
203	Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 308-312.	0.5	127
204	Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 658-663.	0.5	12
205	Active Exercise, Education, and Cognitive Behavioral Therapy for Persistent Disabling Low Back Pain. <i>Spine</i> , 2007, 32, 1578-1585.	1.0	169
206	Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes. <i>Science</i> , 2007, 316, 1336-1341.	6.0	2,040
207	Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. <i>Arthritis and Rheumatism</i> , 2007, 56, 13-20.	6.7	379
208	Influence of inflammatory polyarthritis on cancer incidence and survival: Results from a community-based prospective study. <i>Arthritis and Rheumatism</i> , 2007, 56, 790-798.	6.7	38
209	Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2143-2149.	6.7	214
210	Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. <i>Arthritis and Rheumatism</i> , 2007, 56, 2896-2904.	6.7	292
211	Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2007, 56, 2905-2912.	6.7	522
212	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	9.4	1,298
213	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007, 39, 1431-1433.	9.4	361
214	Mortality in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 871-883.	1.4	140
215	Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. <i>Arthritis Research and Therapy</i> , 2006, 8, 214.	1.6	27
216	The burden of rheumatic disease. <i>Medicine</i> , 2006, 34, 333-335.	0.2	9

#	ARTICLE	IF	CITATIONS
217	Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2006, 54, 1786-1794.	6.7	136
218	Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2006, 54, 2368-2376.	6.7	694
219	Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register. <i>Arthritis and Rheumatism</i> , 2006, 54, 2701-2702.	6.7	106
220	The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. <i>Arthritis and Rheumatism</i> , 2006, 54, 2963-2969.	6.7	101
221	Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 486-492.	0.5	60
222	Developments in rheumatology consultant manpower provision: the BSR/arc Workforce Register 2003-05. <i>Rheumatology</i> , 2006, 45, 1416-1421.	0.9	8
223	Predictors of response to anti-TNF- α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2006, 45, 1558-1565.	0.9	533
224	The world of biologics. <i>Lupus</i> , 2006, 15, 122-126.	0.8	23
225	Predicting persistent disabling low back pain in general practice: a prospective cohort study. <i>British Journal of General Practice</i> , 2006, 56, 334-41.	0.7	54
226	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". <i>Journal of Rheumatology</i> , 2006, 33, 552-7.	1.0	13
227	Dietary β -cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 451-455.	2.2	97
228	Does early rheumatoid arthritis exist?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 37-53.	1.4	25
229	An evaluation of the decision tree format of the American College of Rheumatology 1987 classification criteria for rheumatoid arthritis: Performance over five years in a primary care-based prospective study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2277-2283.	6.7	19
230	Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort. <i>Arthritis and Rheumatism</i> , 2005, 52, 2293-2299.	6.7	256
231	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3596-3602.	6.7	65
232	Dietary β -cryptoxanthin and inflammatory polyarthritis: results from a population-based prospective study. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 451-455.	2.2	91
233	Looking back: rheumatoid arthritis's aetiology, occurrence and mortality. <i>Rheumatology</i> , 2005, 44, iv14-iv17.	0.9	45
234	Risk of lymphoma in patients with RA treated with anti-TNF α agents. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 657-658.	0.5	29

#	ARTICLE	IF	CITATIONS
235	Anti-tumour necrosis factor \hat{A} therapy: can we afford it?. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 969-970.	0.5	6
236	Commentary: Juvenile idiopathic arthritis's issues of definition and causation. <i>International Journal of Epidemiology</i> , 2005, 34, 671-672.	0.9	0
237	Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 11-16.	1.0	161
238	The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 2330-6.	1.0	55
239	Reconciling subject differences in recruitment to clinical trials and clinical practice. <i>Journal of Rheumatology</i> , 2005, 32, 2475-6.	1.0	4
240	Opportunities for prevention of 'clinically significant' knee pain: results from a population-based cross sectional survey. <i>Journal of Public Health</i> , 2004, 26, 277-284.	1.0	42
241	The NOAR Damaged Joint Count (NOAR-DJC): a clinical measure for assessing articular damage in patients with early inflammatory polyarthritis including rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2004, 43, 1519-1525.	2.5	10
242	Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. <i>Rheumatology</i> , 2004, 43, 731-736.	0.9	38
243	Anti-tumour necrosis factor \hat{A} therapy in rheumatoid arthritis: an update on safety. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1538-1543.	0.5	139
244	Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested case-control study. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 843-847.	0.5	106
245	The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. <i>BMJ: British Medical Journal</i> , 2004, 329, 948.	2.4	203
246	Does diet have a role in the aetiology of rheumatoid arthritis?. <i>Proceedings of the Nutrition Society</i> , 2004, 63, 137-143.	0.4	41
247	ICF Core Sets for rheumatoid arthritis. <i>Journal of Rehabilitation Medicine</i> , 2004, 36, 87-93.	0.8	149
248	Anti-tumor necrosis factor \hat{A} therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. <i>Arthritis and Rheumatism</i> , 2004, 50, 1703-1706.	6.7	59
249	Dietary risk factors for the development of inflammatory polyarthritis: Evidence for a role of high level of red meat consumption. <i>Arthritis and Rheumatism</i> , 2004, 50, 3804-3812.	6.7	147
250	Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. <i>Journal of Rheumatology</i> , 2004, 31, 442-7.	1.0	18
251	Methodological issues in conducting and analyzing longitudinal observational studies in rheumatoid arthritis. <i>Journal of rheumatology Supplement, The</i> , 2004, 69, 30-4.	2.2	7
252	The role of diet in susceptibility to rheumatoid arthritis: a systematic review. <i>Journal of Rheumatology</i> , 2004, 31, 1310-9.	1.0	58

#	ARTICLE	IF	CITATIONS
253	Environmental factors and the outcome of rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2003, 17, 717-727.	1.4	53
254	Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis and Rheumatism, 2003, 48, 46-53.	6.7	152
255	Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis. Arthritis and Rheumatism, 2003, 48, 3615-3616.	6.7	19
256	Low back pain in schoolchildren: the role of mechanical and psychosocial factors. Archives of Disease in Childhood, 2003, 88, 12-17.	1.0	187
257	Title is missing!. Spine, 2003, 28, 1195-1202.	1.0	39
258	Predictors of Low Back Pain in British Schoolchildren: A Population-Based Prospective Cohort Study. Pediatrics, 2003, 111, 822-828.	1.0	239
259	Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. Journal of Rheumatology, 2003, 30, 902-4.	1.0	42
260	National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. Journal of Rheumatology, 2003, 30, 958-65.	1.0	122
261	Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. British Journal of Rheumatology, 2002, 41, 767-774.	2.5	26
262	Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology, 2002, 41, 246-252.	0.9	30
263	Low back pain in schoolchildren: occurrence and characteristics. Pain, 2002, 97, 87-92.	2.0	275
264	Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Practice and Research in Clinical Rheumatology, 2002, 16, 707-722.	1.4	229
265	Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis and Rheumatism, 2002, 46, 906-912.	6.7	162
266	Mortality in early inflammatory polyarthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis and Rheumatism, 2002, 46, 2010-2019.	6.7	328
267	Epidemiology and health-related services. Current Opinion in Rheumatology, 2002, 14, 87-88.	2.0	0
268	The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis and Rheumatism, 2001, 44, 323-330.	6.7	105
269	Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis and Rheumatism, 2001, 44, 1033-1042.	6.7	77
270	Time to first occurrence of erosions in inflammatory polyarthritis: Results from a prospective community-based study. Arthritis and Rheumatism, 2001, 44, 1248-1253.	6.7	68

#	ARTICLE	IF	CITATIONS
271	Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. <i>Arthritis and Rheumatism</i> , 2001, 44, 1998-2008.	6.7	75
272	What is the natural history of rheumatoid arthritis?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 27-48.	1.4	47
273	Knee pain in older adults: the latest musculoskeletal "epidemic". <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 89-90.	0.5	26
274	Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis. <i>Journal of Clinical Epidemiology</i> , 2000, 53, 988-996.	2.4	36
275	Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: Results from a large, population-based study. <i>Arthritis and Rheumatism</i> , 1999, 42, 757-762.	6.7	97
276	Estimating the incidence of rheumatoid arthritis: Trying to hit a moving target?. <i>Arthritis and Rheumatism</i> , 1999, 42, 1339-1346.	6.7	136
277	The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2174-2183.	6.7	76
278	1 What is early rheumatoid arthritis?: definition and diagnosis. <i>Bailliere's Clinical Rheumatology</i> , 1997, 11, 13-26.	1.0	35
279	Oral contraceptives and rheumatoid arthritis: Results from a primary care-based incident case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 26, 817-823.	1.6	102
280	Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis. Results from a primary care-based incident case-control study in Norfolk, England. <i>Arthritis and Rheumatism</i> , 1997, 40, 1955-1961.	6.7	337
281	The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996, 39, 363-369.	6.7	2,042
282	NATURAL REMISSION IN INFLAMMATORY POLYARTHRITIS: ISSUES OF DEFINITION AND PREDICTION. <i>Rheumatology</i> , 1996, 35, 1096-1100.	0.9	112
283	CLINICAL AUDIT: CHANGING PATTERNS OF RHEUMATOLOGY MANPOWER AND PRACTICE IN THE UK IN THE 1990s. <i>Rheumatology</i> , 1996, 35, 483-487.	0.9	9
284	Disease assessment indices: activity, damage and severity. <i>Bailliere's Clinical Rheumatology</i> , 1995, 9, 267-285.	1.0	35
285	Selection of study population in the development of rheumatic disease criteria: comment on the article by the american college of rheumatology diagnostic and therapeutic criteria committee. <i>Arthritis and Rheumatism</i> , 1995, 38, 722-722.	6.7	9
286	MEASURING OUTCOME IN RHEUMATOID ARTHRITIS—WHICH MEASURES ARE SUITABLE FOR ROUTINE CLINICAL USE?. <i>Rheumatology</i> , 1995, 34, 802-804.	0.9	6
287	THE INCIDENCE OF RHEUMATOID VASCULITIS IN THE NORWICH HEALTH AUTHORITY. <i>Rheumatology</i> , 1994, 33, 832-833.	0.9	50
288	THE INCIDENCE OF RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER. <i>Rheumatology</i> , 1994, 33, 735-739.	0.9	377

#	ARTICLE	IF	CITATIONS
289	Life events and the onset of rheumatoid arthritis. <i>Journal of Psychosomatic Research</i> , 1994, 38, 837-847.	1.2	19
290	THE PREVALENCE OF DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS IN WHITES AND INDIAN ASIAN IMMIGRANTS IN LEICESTER CITY, UK. <i>Rheumatology</i> , 1992, 31, 679-682.	0.9	58
291	A PATIENT WITH RHEUMATOID ARTHRITIS AND LYMPHOMA. <i>Rheumatology</i> , 1992, 31, 107-112.	0.9	5
292	Short-term effects of antirheumatic drugs. <i>Bailliere's Clinical Rheumatology</i> , 1992, 6, 117-140.	1.0	11
293	RHEUMATOLOGY MANPOWER IN THE 1990s. <i>Rheumatology</i> , 1991, 30, 119-122.	0.9	7
294	Outcome in patients hospitalised for psoriatic arthritis. <i>Clinical Rheumatology</i> , 1989, 8, 261-265.	1.0	35
295	Vasculitis of the gall bladder in rheumatoid arthritis and systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 1987, 6, 287-289.	1.0	24
296	Joint sepsis as a complication of sero-negative arthritis. <i>Clinical Rheumatology</i> , 1985, 4, 51-54.	1.0	5
297	Neoplasms of the immune system in rheumatoid arthritis. <i>American Journal of Medicine</i> , 1985, 78, 22-28.	0.6	178
298	A Study of Lymph Node Lymphocytes in Rheumatoid Arthritis. , 1985, 186, 1027-1032.		4
299	CAUSE OF DEATH IN RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1984, 23, 92-99.	0.9	212
300	221.â€fRisk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour Necrosis Factor Alpha Inhibition. <i>Rheumatology</i> , 0, , .	0.9	0
301	220.â€fPredicting Successful Long-Term Treatment with Tumour Necrosis Factor Alpha Inhibitors in Patients with Psoriatic Arthritis. <i>Rheumatology</i> , 0, , .	0.9	0